As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.

India Biosimilar Market: By Molecule: Human Growth Hormone, Insulin Glargine, Interferon, Erythropoietin, Monoclonal Antibodies, Others; By Manufacturing Type; By Application: Auto-Immune Diseases, Blood Disorder, Others; Historical Market and Forecast (2016-2026); Market Dynamics; Competitive Landscape; Industry Events and Developments

India Biosimilar Market Outlook

The India biosimilar market size reached a value of almost USD 633 million in the year 2020. The market is further expected to grow at a CAGR of 11% between 2021 and 2026.

 

Expansion of Healthcare Infrastructure to Propel the Biosimilar Market in India Ahead

The market in India is being driven by the expansion of the healthcare infrastructure and the increasing penetration of the pharmaceutical industry in the region. The regional market of biosimilar is driven by several factors such as low production costs, slender regulations by the government, and the availability of cheap and skilled labour within the region. The growing geriatric population within India is further accelerating the market growth of biosimilar. Further, the patents of numerous blockbuster biologic drugs have expired, and some of the blockbuster drugs are further expected to have their patent protection expire in the upcoming years, thus, offering tremendous market opportunities for biosimilar manufacturers in India in the forecast period.

 

India Biosimilar Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Biosimilar: Industry Definition and Segmentation

Biosimilars are also known as subsequent entry biologics (SEBs) or follow-on biologics. These are the FDA-approved biotherapeutic products, which share the same properties as their reference biologics. These can be manufactured only after the expiration of the reference product’s patent.

The market is divided on the basis of molecule into:

  • Human Growth Hormone
  • Insulin Glargine
  • Interferon
  • Erythropoietin
  • Monoclonal Antibodies
  • Granulocyte Colony Stimulating Factor (G-CSF)
  • Others

Based on manufacturing type, the market is segmented into:

  • In-House Manufacturing
  • Contract Manufacturing

On the basis of indication, the market is divided into:

  • Auto-Immune Diseases
  • Blood Disorder
  • Diabetes
  • Oncology
  • Growth Deficiency
  • Female Infertility
  • Others

 

Growing Incidences of Chronic Diseases to Bolster the Demand for Biosimilar in India

The biosimilar market in India is driven by the rising incidences of chronic diseases, such as auto-immune diseases, cancers, growth hormone deficiency, kidney failure, diabetes, infectious diseases, rheumatoid arthritis, haematological disorders, diabetes, CVDs, and others, within the country. The growing demand for biosimilars due to their cost-effectiveness is further aiding industry growth. The market is finding further impetus for its growth in the several cost-saving initiatives undertaken by governments as well as third-party payers, which, as a result, are encouraging the use of biosimilars as opposed to branded biologics, thereby propelling the demand for biosimilars. However, some factors, such as negative perception from physicians, lower price differential as compared to small-molecule generics, patent extensions, and others, are hampering the growth of the market in India.

 

Key Industry Players in the India Biosimilar Market

The report gives a detailed analysis of the following key players in the India biosimilar market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • Biocon Limited
  • Dr. Reddy’s Laboratories Ltd
  • Cadila Healthcare Limited
  • Alkem Laboratories Ltd.
  • Others

The comprehensive EMR report provides an in-depth assessment of the industry based on the Porter's five forces model along with giving a SWOT analysis.

 

REPORT FEATURES DETAILS
Base Year 2020
Historical Period 2016-2020
Forecast Period 2021-2026
Scope of the Report Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Molecule, Manufacturing Type, Application
Breakup by Molecule Human Growth Hormone, Insulin Glargine, Interferon, Erythropoietin, Monoclonal Antibodies, Granulocyte Colony Stimulating Factor (G-CSF), Others
Breakup by Manufacturing Type In-House Manufacturing, Contract Manufacturing
Breakup by Application Auto-Immune Diseases, Blood Disorder, Diabetes, Oncology, Growth Deficiency, Female Infertility, Others
Market Dynamics SWOT, Porter's Five Forces, EMR’s Key Indicators for Price and Demand
Competitive Landscape Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications
Companies Covered Biocon Limited, Dr. Reddy’s Laboratories Ltd, Cadila Healthcare Limited, Alkem Laboratories Ltd., Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Snapshot
    6.1    India
7    Industry Opportunities and Challenges
8    India Biosimilar Market Analysis

    8.1    Key Industry Highlights
    8.2    India Biosimilar Historical Market (2016-2020) 
    8.3    India Biosimilar Market Forecast (2021-2026)
    8.4    India Biosimilar Market by Molecule
        8.4.1    Human Growth Hormone
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2016-2020)
            8.4.1.3    Forecast Trend (2021-2026)
        8.4.2    Insulin Glargine
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2016-2020)
            8.4.2.3    Forecast Trend (2021-2026)
        8.4.3    Interferon
            8.4.3.1    Market Share
            8.4.3.2    Historical Trend (2016-2020)
            8.4.3.3    Forecast Trend (2021-2026)
        8.4.4    Erythropoietin
            8.4.4.1    Market Share
            8.4.4.2    Historical Trend (2016-2020)
            8.4.4.3    Forecast Trend (2021-2026)
        8.4.5    Monoclonal Antibodies
            8.4.5.1    Market Share
            8.4.5.2    Historical Trend (2016-2020)
            8.4.5.3    Forecast Trend (2021-2026)
        8.4.6    Granulocyte Colony Stimulating Factor (G-CSF)
            8.4.6.1    Market Share
            8.4.6.2    Historical Trend (2016-2020)
            8.4.6.3    Forecast Trend (2021-2026)
        8.4.7    Others 
    8.5    India Biosimilar Market by Manufacturing Type
        8.5.1    In-House Manufacturing
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2016-2020)
            8.5.1.3    Forecast Trend (2021-2026)
        8.5.2    Contract Manufacturing
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2016-2020)
            8.5.2.3    Forecast Trend (2021-2026)
    8.6    India Biosimilar Market by Application
        8.6.1    Auto-Immune Diseases
            8.6.1.1    Market Share
            8.6.1.2    Historical Trend (2016-2020)
            8.6.1.3    Forecast Trend (2021-2026)
        8.6.2    Blood Disorder
            8.6.2.1    Market Share
            8.6.2.2    Historical Trend (2016-2020)
            8.6.2.3    Forecast Trend (2021-2026)
        8.6.3    Diabetes
            8.6.3.1    Market Share
            8.6.3.2    Historical Trend (2016-2020)
            8.6.3.3    Forecast Trend (2021-2026)
        8.6.4    Oncology
            8.6.4.1    Market Share
            8.6.4.2    Historical Trend (2016-2020)
            8.6.4.3    Forecast Trend (2021-2026)
        8.6.5    Growth Deficiency
            8.6.5.1    Market Share
            8.6.5.2    Historical Trend (2016-2020)
            8.6.5.3    Forecast Trend (2021-2026)
        8.6.6    Female Infertility
            8.6.6.1    Market Share
            8.6.6.2    Historical Trend (2016-2020)
            8.6.6.3    Forecast Trend (2021-2026)
        8.6.7    Others
9    Market Dynamics
    9.1    SWOT Analysis
        9.1.1    Strengths
        9.1.2    Weaknesses
        9.1.3    Opportunities
        9.1.4    Threats
    9.2    Porter’s Five Forces Analysis
        9.2.1    Supplier’s Power
        9.2.2    Buyers Power
        9.2.3    Threat of New Entrants
        9.2.4    Degree of Rivalry
        9.2.5    Threat of Substitutes
    9.3    EMR’s Key Indicators for Demand
    9.4    EMR’s Key Indicators for Price
10    Value Chain Analysis
11    Competitive Landscape

    11.1    Market Structure
    11.2    Company Profiles
        11.2.1    Biocon Limited
            11.2.1.1    Company Overview
            11.2.1.2    Product Portfolio
            11.2.1.3    Demographic Reach and Achievements
            11.2.1.4    Certifications
        11.2.2    Dr. Reddy’s Laboratories Ltd
            11.2.2.1    Company Overview
            11.2.2.2    Product Portfolio
            11.2.2.3    Demographic Reach and Achievements
            11.2.2.4    Certifications
        11.2.3    Cadila Healthcare Limited
            11.2.3.1    Company Overview
            11.2.3.2    Product Portfolio
            11.2.3.3    Demographic Reach and Achievements
            11.2.3.4    Certifications
        11.2.4    Alkem Laboratories Ltd.
            11.2.4.1    Company Overview
            11.2.4.2    Product Portfolio
            11.2.4.3    Demographic Reach and Achievements
            11.2.4.4    Certifications
        11.2.5    Others
12    Industry Events and Developments

 

List of Figures and Tables

1.    India Biosimilar Market: Key Industry Highlights, 2016 and 2026
2.    India Biosimilar Historical Market: Breakup by Molecule (USD Million), 2016-2020
3.    India Biosimilar Market Forecast: Breakup by Molecule (USD Million), 2021-2026
4.    India Biosimilar Historical Market: Breakup by Manufacturing Type (USD Million), 2016-2020
5.    India Biosimilar Market Forecast: Breakup by Manufacturing Type (USD Million), 2021-2026
6.    India Biosimilar Historical Market: Breakup by Application (USD Million), 2016-2020
7.    India Biosimilar Market Forecast: Breakup by Application (USD Million), 2021-2026
8.    India Biosimilar Market Structure

Purchase Full Report

Mini Report

$1499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$2699
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$3699
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$4699
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

RIGHT PEOPLE

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

RIGHT METHODOLOGY

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

RIGHT PRICE

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

RIGHT SUPPORT

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

Similar Reports





NEWSLETTER